News Focus
News Focus
icon url

asuhowe

05/16/08 9:04 AM

#17231 RE: Market_Fest4 #17227

Yeah.. 40, right..
Dream on..

I start to like you Market, then you get all delusional again..
icon url

laddadg

05/16/08 1:26 PM

#17241 RE: Market_Fest4 #17227

Normally, I try to stick with the basics and avoid topics regarding market manipulation. But this morning's action is extremely suspicious.

I placed a buy order for 1,400 shares @0.66 at 11:40 AM this morning, and it took 14 transactions of 100 shares each to finally fill this order. Each transaction was separated by about 4-5 minutes and the entire order took more than 1 hour to fill. In fact, every time some shares sold at a higher level, another 100 share transaction was completed (to once again move the price down).

Someone is doing everything possible to keep a lid on this, and with volumes this low, appears to be succeeding.

Don

icon url

striaterminalis

05/16/08 10:29 PM

#17250 RE: Market_Fest4 #17227

40 may be a bit too ebullient, but I have to say I find the gist of the scenario believable. After skimming through the presentation yesterday, I find myself in the odd state of mind of being impressed by Stoll and COR. I've been on the fence about management, but when you consider what Stoll has done after the ADHD debacle, you have to admit that he has (as they say in sports all too often now) put COR in a position to succeed. They have good low and high impacts coming on line, they are testing them to make sure they don't create that artifact that seems to trigger a special FDA neurosis, and they are in the midst of what must be considered a slam dunk RD trial (at least as "slam dunky" as you can get in biotech) that may resurrect the reputation of Ampakines in one stroke.

So, after holding COR for longer than anyone should be comfortable admitting, I have to say that now, finally, I'm impressed. The RD trial could be the turning point we have all been waiting for. If this is Stoll's work, good job. He handed over a good substrate for Varney to work with.